 LYON, France, January 14, 2021 -- EDAP TMS SA Nasdaq: EDAP the Company, the global leader in robotic energy based therapies, announced today positive 24 month interim results from the HIFI study comparing outcomes from high intensity focused ultrasound HIFU versus radical prostatectomy RP in a population of prostate cancer patients. This study is sponsored by the French Association of Urology AFU and supported by the French Ministry of Health. The results were presented at the AFU Congress in November 2020. 